They need it for their early june usa biotech networking conference.
- trial fully enrolled
- no safety issues
- all participants still on
- tox study done with zero issues
- efficacy likely to show stabalisation or dare to say improvement
- works with exon skipping
- yet to partner with anyone
- inflammation now better understood to be key driver for best treatment outcomes
- show us the money
When US tox study due, page-7
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.2¢ |
Change
0.002(2.22%) |
Mkt cap ! $82.94M | |||
| Open | High | Low | Value | Volume |
| 8.9¢ | 9.2¢ | 8.8¢ | $69.71K | 769.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 35742 | 9.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.2¢ | 84100 | 2 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
9.2¢ |
Change
0.002 ( 3.37 %) |
||||
| Open | High | Low | Volume | ||
| 8.9¢ | 9.2¢ | 8.8¢ | 138646 | ||
| Last updated 15.59pm 14/06/2024 ? | |||||
| PER (ASX) Chart |